Mineralys Therapeutics, INC Form 4 insider transactions

Mineralys Therapeutics Director Daphne Karydas is set to receive 6,200 Restricted Stock Units and options for 8,300 shares of common stock on February 19, 2026.

Mineralys Therapeutics Director and 10% owner Brian Taylor Slingsby reported the grant and subsequent transfer of Restricted Stock Units and stock options to Catalys Pacific Fund, LP.

Mineralys Therapeutics Director and 10% owner Srinivas Akkaraju reported planned future acquisitions of 6,200 Restricted Stock Units and 8,300 stock options.

Mineralys Therapeutics Director Derek DiRocco was granted 6,200 Restricted Stock Units and 8,300 stock options, which he holds for RA Capital Management funds.

Mineralys Therapeutics' Chief Medical Officer, David Malcom Rodman, was granted 38,400 Restricted Stock Units and 51,300 stock options.

Mineralys Therapeutics CFO Adam Levy received significant equity awards, including 39,900 Restricted Stock Units and 53,300 stock options, as part of his compensation.

Mineralys Therapeutics' Chief Medical Officer, David Malcom Rodman, executed multiple stock option exercises and subsequent sales of common stock in February 2026 under a pre-arranged 10b5-1 trading plan.

Mineralys Therapeutics' Chief Medical Officer, David Malcom Rodman, exercised stock options and sold an equal number of shares under a pre-arranged 10b5-1 trading plan.

Mineralys Therapeutics' Chief Medical Officer, David Malcom Rodman, executed a pre-planned sale of 416 common shares following an option exercise.

Mineralys Therapeutics' Chief Medical Officer, David Malcom Rodman, exercised stock options and subsequently sold common stock under a pre-arranged 10b5-1 trading plan.

Mineralys Therapeutics CEO Jon Congleton sold 16,236 shares of common stock on January 12, 2026, under a pre-arranged 10b5-1 trading plan.

Mineralys Therapeutics CFO Adam Levy sold 10,758 shares of common stock for a weighted-average price of $32.1364 per share under a pre-arranged 10b5-1 trading plan.

Mineralys Therapeutics' Chief Medical Officer, David Malcom Rodman, sold shares of common stock in January 2026 following the exercise of stock options, pursuant to a pre-arranged 10b5-1 trading plan.

Mineralys Therapeutics' Chief Medical Officer, David Malcom Rodman, exercised a significant number of stock options and subsequently sold a portion of the acquired common stock in early January 2026, as per a pre-arranged 10b5-1 trading plan.

Mineralys Therapeutics CEO Jon Congleton exercised stock options to acquire 24,082 shares of common stock, increasing his direct beneficial ownership.

A director and 10% owner of Mineralys Therapeutics, Brian Taylor Slingsby, plans to sell 1,000,000 shares of common stock for $43.35 per share on November 20, 2025, under a Rule 10b5-1 plan.

Mineralys Therapeutics CFO Adam Levy reported exercising stock options and selling common stock on November 11, 2025, alongside transfers to an ex-spouse.

Mineralys Therapeutics CEO Jon Congleton filed a Form 4 detailing planned sales of nearly 200,000 shares of common stock under a 10b5-1 plan.

Mineralys Therapeutics Director Daphne Karydas exercised stock options and subsequently sold all 15,000 acquired shares for a significant gain.

Mineralys Therapeutics Director Alexander M. Gold sold over $1.57 million in company common stock after exercising stock options under a Rule 10b5-1 plan.

Mineralys Therapeutics CFO Adam Levy sold over 10,000 shares of common stock for approximately $450,000 through a pre-arranged 10b5-1 trading plan.

Mineralys Therapeutics CEO Jon Congleton sold 15,100 shares of common stock on October 13, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Mineralys Therapeutics' Chief Medical Officer, David Malcom Rodman, reported a planned sale of 10,369 shares of common stock for approximately $43.01 per share, scheduled for October 15, 2025, under a pre-arranged 10b5-1 trading plan.

Mineralys Therapeutics' Chief Medical Officer, David Malcom Rodman, sold 11,367 shares of common stock on September 15, 2025, through a pre-arranged 10b5-1 trading plan.

A fund associated with Mineralys Therapeutics Director Srinivas Akkaraju acquired 588,235 shares of common stock for approximately $15 million.

RA Capital Management and affiliated entities acquired over 1.1 million shares of Mineralys Therapeutics common stock for $25.5 per share.

Mineralys Therapeutics' Chief Medical Officer, David Rodman, exercised stock options and subsequently sold a portion of his common stock holdings under a pre-arranged trading plan.

Mineralys Therapeutics' CFO and Secretary, Adam Scott Levy, sold a total of 73,678 shares of common stock across four transactions in late July 2025, executed under a Rule 10b5-1 trading plan.

Mineralys Therapeutics' CEO, Jon Congleton, executed a pre-scheduled sale of 15,884 common shares on July 11, 2025, as part of a Rule 10b5-1 trading plan.

Mineralys Therapeutics' CFO and Secretary, Adam Scott Levy, sold 10,758 shares of common stock on July 11, 2025, through a pre-arranged Rule 10b5-1 trading plan.